Low dose systemic Rose Bengal as a checkpoint inhibitor to IL-17, IL-23...and thus IL-6 inhibitor a | PVCT Message Board Posts

Provectus Biopharmaceuticals, Inc.

  PVCT website

PVCT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  54245 of 54455  at  9/15/2020 11:12:18 PM  by

pacificnorthwest1

The following message was updated on 9/15/2020 11:57:32 PM.

 In response to msg 54195 by  vorlon1966
view thread

Re: Low dose systemic Rose Bengal as a checkpoint inhibitor to IL-17, IL-23...and thus IL-6 inhibitor as a path to new therapies.

you wrote:
 This study launched new research by independent research firms to study RB as a checkpoint inhibitor to IL-17, IL-23, IL-6 and other IL..,to which implications can be read below.
 
 
I wrote:
vorlon-- 
what's the deal with all these IL numbers ?
When you say "and other IL . . ." is it possible a longer list of IL numbers (than your numbers mentioned in this post), may become involved with Rose Bengal mechanism of action? 
I ask...
A few hours after learning my 40 yr old nephew, who is having a better quality image at U of MI (MRI - as I type) for possible two bilateral large kidney masses. Help??
He is happily married with 5 kids.
Say it isn't so. 
I know cryoablation has been used & approved for kidney cancer in USA. Stats in link below, suggest kidney cryoablation should be done in conjunction with the best possible immunotherapy, if it is a tx option. 
I wonder if the necrosis issue may limit injection of kidneys with something like rose bengal?  Or if it depend on size?
Kidney toxicity concerns should mean many drugs/immunotherapies would not be ideal for kidneys!  
Could there be some hope with low toxic PV-10 / RBD ?
Independent trial IND ??
Right To Try perhaps? 
Too many questions.
All possible info is welcomed 
pnw1 
 
 -----------------------------------------
2019 SITC Conference -Summary 

 

 

P505 Abscopal immunity achieved via in situ vaccination using a novel combination of cryoablation and Interleukin-12

Maura Vrabel, Francis Gillam, PhD, Jared Hopkins, Khue Nguyen, PhD, David Zaharoff, PhD
NC State University, Raleigh, NC, United States
Correspondence: David Zaharoff (dazaharo@ncsu.edu)

 

 
 
Background

Clinically, cryoablation is used to treat various types of cancers including certain prostate, liver and kidney tumors

 
Results

Cryoablation of a single primary tumor resulted in a tumor-free survival rate of 40%. The addition of R848 or DMXAA did not significantly enhance survival, while adding CS/IL-12 resulted in a 90% survival rate (Figure 1). Cured mice were rechallenged with live MB49 cells and then given no further treatment. As of day 70 post rechallenge, the number of tumor free mice out of total survivors were cryo alone (3/4), cryo + CS/IL-12 (5/7), cryo + R848 (2/5), and cryo + DMXAA (1/4). In the bilateral model, the median survival of the cryo + CS/IL-12 group was significantly longer (p = 0.0016) at 49.5 days compared to 26 days for cryo alone (Figure 2). Furthermore, one mouse treated with cryo + CS/IL-12 experienced a complete response up to 90 days post tumor implantation.

Conclusions

IL-12 formulated with chitosan and delivered after cryoablation is superior in treating not only a primary tumor, but also in inducing an abscopal effect on a distant, untreated tumor. Of note, neither DMXAA nor R848 was formulated in a delivery vehicle, as we have yet to optimize these agonists. This work supports further study of cryoablation and IL-12 for in situ vaccination and cancer immunotherapy.

 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 147
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






Financial Market Data provided by
.


Loading...